Thrive Wealth Management LLC Invests $51,000 in Caribou Biosciences, Inc. (NASDAQ:CRBU)

Thrive Wealth Management LLC bought a new position in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 32,000 shares of the company’s stock, valued at approximately $51,000.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Renaissance Technologies LLC bought a new position in shares of Caribou Biosciences in the second quarter worth $2,432,000. Dimensional Fund Advisors LP increased its stake in Caribou Biosciences by 25.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after acquiring an additional 536,162 shares during the last quarter. PFM Health Sciences LP raised its holdings in shares of Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after acquiring an additional 223,299 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Caribou Biosciences during the 2nd quarter valued at about $341,000. Finally, Geode Capital Management LLC grew its holdings in shares of Caribou Biosciences by 6.5% during the third quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after purchasing an additional 124,782 shares in the last quarter. 77.51% of the stock is currently owned by hedge funds and other institutional investors.

Caribou Biosciences Stock Performance

Shares of Caribou Biosciences stock opened at $1.53 on Tuesday. Caribou Biosciences, Inc. has a 52-week low of $1.50 and a 52-week high of $8.33. The company has a fifty day moving average of $1.88 and a 200-day moving average of $2.00. The stock has a market capitalization of $138.54 million, a price-to-earnings ratio of -0.93 and a beta of 2.34.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The business had revenue of $2.02 million during the quarter, compared to analyst estimates of $3.37 million. On average, equities research analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on CRBU shares. Bank of America lowered their target price on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Citigroup dropped their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Finally, HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Friday, November 15th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Caribou Biosciences currently has an average rating of “Buy” and a consensus target price of $10.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.